Evidence map›Paper›PMID 31131207›Full record

ArticleCurrent stem cell reports2018

Peripheral blood stem cell mobilization; a look ahead.

Louis M Pelus, Hal E Broxmeyer

Abstract read
In one paragraph

Article in Current stem cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  5. Article
  6. Review
  7. Ex Vivo Expansion and Homing of Human Cord Blood Hematopoietic Stem Cells.Advances in experimental medicine and biology · 2023
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Targeting CXCR4 in AML and ALL.Frontiers in oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Louis M PelusDepartment of Microbiology & Immunology, Indiana University School of Medicine, 950 W Walnut Street, R2-301, Indianapolis, IN 46202.
Hal E BroxmeyerDepartment of Microbiology & Immunology, Indiana University School of Medicine, 950 W Walnut Street, R2-301, Indianapolis, IN 46202.
Indiana University – Purdue University Indianapolis · US

Funding

Project-005U54DK106846 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Reuben Kapur, Karen Elizabeth Pollok · 2015 to 2026
$9.7M
MECHANISMS OF SYNERGISTIC REGULATION OF STEM/PROGENITORSR01HL056416 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI BROXMEYER, HAL E. · 1996 to 2017
$6.0M
Enhancing Engraftment of Cord Blood by CD26 InhibitionR01HL112669 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI BROXMEYER, HAL E., FARAG, SHERIF S · 2012 to 2016
$3.6M
Role of PGE2 and other eicosanoids in hematopoietic stem cell functionR01HL096305 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI PELUS, LOUIS M · 2010 to 2018
$3.5M
Controlling Influences of Oxygen Tension and CD26/DPP4 Enzymatic Activity on Regulation of Hematopoietic Stem/Progenitor Cells and Hematopoiesis During Health, Ageing, and DiseaseR35HL139599 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI BROXMEYER, HAL E. · 2018 to 2021
$3.1M
Inhibition of PGE2 for mobilization of autologous peripheral blood stem cellsR01CA182947 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FARAG, SHERIF S, PELUS, LOUIS M · 2014 to 2018
$1.6M
A megakaryocyte/PGE2/osteoblast triad in the normal and aged nicheR01AG046246 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI KACENA, MELISSA A, PELUS, LOUIS M · 2013 to 2017
$1.1M
NCI NIH HHS R01 CA182947NHLBI NIH HHS R01 HL056416NHLBI NIH HHS R01 HL096305NHLBI NIH HHS R01 HL112669NHLBI NIH HHS R35 HL139599NIA NIH HHS R01 AG046246NIDDK NIH HHS U54 DK106846
6 · The paper itself

Abstract

the purpose of reviewMobilized peripheral blood is the predominant source of stem and progenitor cells for hematologic transplantation. Successful transplant requires sufficient stem cells of high enough quality to recapitulate lifelong hematopoiesis, but in some patients and normal donors, reaching critical threshold stem cell numbers are difficult to achieve. Novel strategies, particularly those offering rapid mobilization and reduced costs, remains an area of interest.This review summarizes critical scientific underpinnings in understanding the process of stem cell mobilization, with a focus on new or improved strategies for their efficient collection and engraftment. RECENT

findingsStudies are described that provide new insights into the complexity of stem cell mobilization. Agents that target new pathways such HSC egress, identify strategies to collect more potent competing HSC and new methods to optimize stem cell collection and engraftment are being evaluated. SUMMARY: Agents and more effective strategies that directly address the current shortcomings of hematopoietic stem cell mobilization and transplantation and offer the potential to facilitate collection and expand use of mobilized stem cells have been identified.

Indexed as

Hematopoietic stem cellshigh engrafting stem cellsHSC egresshypoxic collectionPeripheral blood stem cell mobilizationstem cell collection

Identifiers

PMID31131207
PMCPMC6532982
OpenAlexW2897430221

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.